当前位置: 首页 >> 检索结果
1. Insights Into Recovery From Acute Fulminant Myocarditis Following Successful Treatment With Ruxolitinib by Comprehensive Single-Cell Profiling.
作者: Juan Qin.;Mandar A Aras.;Evelyn J Song.;Andrew J Connolly.;Lylybell Zhou.;Connor O'Brien.;Joe-Elie Salem.;Arun Padmanabhan.;Javid J Moslehi.
来源: Circulation. 2025年151卷25期1814-1817页 2. Response by Murai et al to Letter Regarding Article, "Impact of Post-PCI Lipid Core Burden Index on Angiographic and Clinical Outcomes: Insights From NIRS-IVUS".
作者: Woohyeun Kim.;Hyungdon Kook.;Yonggu Lee.;Young-Hyo Lim.
来源: Circ Cardiovasc Imaging. 2025年e018586页 6. Dynamic Updating Strategies to Assess Hospital Performance of Surgical Aortic Valve Replacement.
作者: Jackie Pollack.;Wei Yang.;George J Arnaoutakis.;Michael J Kallan.;Stephen E Kimmel.
来源: Circ Cardiovasc Qual Outcomes. 2025年e011608页
Prediction models determining expected outcomes are infrequently updated (ie, static), which may reduce accuracy and misclassify hospital performance over time. Dynamic models incorporate changes over time and may improve accuracy and fairness in hospital comparisons. This study evaluated whether dynamic updating, compared with a static model, altered hospital rankings and outlier detection among surgical aortic valve replacement patients.
8. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
作者: Samer Al Said.;Siddharth M Patel.;Robert P Giugliano.;David A Morrow.;Erica L Goodrich.;Sabina A Murphy.;Bruce Hug.;Sanobar Parkar.;Shih-Ann Chen.;Shaun G Goodman.;Boyoung Joung.;Robert G Kiss.;Wojciech Wojakowski.;Jeffrey I Weitz.;Dan Bloomfield.;Marc S Sabatine.;Christian T Ruff.
来源: Circulation. 2025年
Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.
9. Response by Wang et al to Letter Regarding Article, "Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis".14. Implementing Precision Medicine for Dilated Cardiomyopathy: Insights From the DCM Consortium.
作者: Elizabeth Jordan.;Hanyu Ni.;Patricia Parker.;Daniel D Kinnamon.;Anjali Owens.;Brian Lowes.;Chetan Shenoy.;Cindy M Martin.;Daniel P Judge.;Daniel P Fishbein.;Douglas Stoller.;Elina Minami.;Evan P Kransdorf.;Frank Smart.;Garrie J Haas.;Gordon S Huggins.;Gregory A Ewald.;Jamie Diamond.;Jane E Wilcox.;Javier Jimenez.;Jessica Wang.;Jose Tallaj.;Mark H Drazner.;Mark Hofmeyer.;Matthew T Wheeler.;Omar Wever Pinzon.;Palak Shah.;Stephen S Gottlieb.;Stuart Katz.;Supriya Shore.;W H Wilson Tang.;Ray E Hershberger.; .
来源: Circ Genom Precis Med. 2025年e005078页 15. Mechanistic Pathways Underlying Genetic Predisposition to Atrial Fibrillation Are Associated With Different Cardiac Phenotypes and Cardioembolic Stroke Risk.
作者: Parag R Gajendragadkar.;Adam Von Ende.;Federico Murgia.;Alison Offer.;C Fielder Camm.;Rohan S Wijesurendra.;Barbara Casadei.;Jemma C Hopewell.
来源: Circ Genom Precis Med. 2025年18卷3期e004932页
Genome-wide association studies have clustered candidate genes associated with atrial fibrillation (AF) into biological pathways reflecting different pathophysiological mechanisms. We investigated whether these pathways associate with distinct intermediate phenotypes and confer differing risks of cardioembolic stroke.
18. Identifying a Heterogeneous Effect of Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial.
作者: Sachin J Shah.;Jay M Iyer.;Leila Agha.;Yuchiao Chang.;Jeffrey M Ashburner.;Steven J Atlas.;David D McManus.;Patrick T Ellinor.;Steven A Lubitz.;Daniel E Singer.
来源: Circ Cardiovasc Qual Outcomes. 2025年e011482页
One-time atrial fibrillation (AF) screening trials in older adults have produced mixed results. In a secondary analysis of the VITAL-AF trial, we aimed to identify a subset of people in whom such screening is effective, using effect-based and risk-based approaches.
19. Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: the PRINCE Randomized Clinical Trial.
作者: Massimiliano Greco.;Gaetano Lombardi.;Claudia Brusasco.;Marina Pieri.;Agostino Roasio.;Fabrizio Monaco.;Levan Berikashvili.;Alessandro Belletti.;Francesco Meroi.;Stefano Fresilli.;Aituar Kabibulatov.;Giuseppe Giardina.;Andrea Russo.;Federico Mattia Oliva.;Sergey Efremov.;Rosalba Lembo.;Lini Wang.;Simone Vietri.;Elena Momesso.;Filippo D'Amico.;Kristina Kadantseva.;Rosa Labanca.;Pavel Ryzhkov.;Marilena Marmiere.;Valery Subbotin.;Alessandro Pruna.;Nerlep Rana.;Francesca Livi.;Hugo Mantilla-Gutierrez.;Fabio Guarracino.;Lorenzo Schiavoni.;Ivan Šitum.;Marco Micali.;Stefano Bosso.;Anastasia Smirnova.;Giuseppe Fresta.;Andrey Cherednichenko.;Luigi Beretta.;Giacomo Monti.;Lian Kah Ti.;Pasquale Sansone.;Francesco Corradi.;Maurizio Cecconi.;Andrey Yavorovskiy.;Chong Lei.;Aidos Konkayev.;Tiziana Bove.;Valery Likhvantsev.;Alberto Zangrillo.;Giovanni Landoni.;Rinaldo Bellomo.;Remo Daniel Covello.;Stefano Turi.; .
来源: Circulation. 2025年
Major noncardiac surgery carries high rates of postoperative myocardial injury and other complications. Remote ischemic preconditioning (RIPC) was reported to decrease these complications. However, such supportive evidence lacks robustness.
20. How a Topological Mindset May Offer Extra Control During Mapping and Ablation of Left-Sided Reentrant Atrial Tachycardia.
作者: Mattias Duytschaever.;Maarten De Smet.;Jordi Martens.;Milad El Haddad.;Benjamin De Becker.;Clara Francois.;Rene Tavernier.;Robin Van den Abeele.;Sander Hendrickx.;Nele Vandersickel.;Jean-Benoit Le Polain de Waroux.;Sebastien Knecht.
来源: Circ Arrhythm Electrophysiol. 2025年e013780页
Reentry (macro or localized) is historically described as multiple pathways that are separated by barriers (either anatomic or functional) and involve active and passive loops (identified by electro-anatomic and entrainment mapping, EAM/ETM). Some reentrant atrial tachycardia (AT) cases are characterized by challenging activation patterns and unexpected ablation responses. A recent translational study, focusing on topology and the role of boundaries, suggests that thinking topology within EAM/ETM might offer extra control during mapping and ablation of reentrant AT. We aimed to propose and prospectively validate a workflow (EAM/ETM+TOP) in which we integrate topological thinking within an EAM/ETM workflow for mapping and ablation of left-sided (left atrium) AT.
|